Chief Executive Officer and Director
Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.
Chief Financial Officer
Marcel Konrad joined Medexus in 2021 from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller. Mr. Konrad brings over 20 years of experience in Accounting, Finance and Business across various global markets that include Chief Financial Officer at Santen Inc, a US subsidiary of Santen Pharmaceuticals, a Japanese eye care company and various roles at Novartis both in the US and Switzerland. Mr. Konrad was an Auditor with KPMG. He holds an International MBA from the University of San Diego and has a Masters of Business Administration from HEC Lausanne, Switzerland. Mr. Konrad is an active US CPA.
General Manager, U.S. Operations
Michael Adelman joined Medexus in 2020 from Aptevo Therapeutics, where he led all commercial functions as SVP, Commercial Operations. Mr. Adelman has over 25 years of life-science commercial experience, including leadership roles at Emergent BioSolutions, Cangene, Adolor, and AstraZeneca. Mr. Adelman holds a Bachelor of Science in Finance from Northeastern University and Master of Business Administration from New York University’s Stern School of Business.
Senior Vice President of Business Development and Strategy
Michael Pine joined Medexus in 2020 from Lupin Pharmaceuticals, where he served as SVP BD&L, responsible for expanding further into branded specialty products. Mr. Pine has over 20 years of experience as a pharmaceutical industry executive and business leader with a diverse background in both large and small pharmaceutical companies that includes functions in: business development & licensing, M&A, investment banking, strategy, marketing, US managed markets, and operations. Prior positions include senior roles at companies such as Aralez, Novartis, Kos Pharmaceuticals, Organon, Pfizer, and JP Morgan Chase. Mr. Pine has a BS in Consumer Economics from Cornell University and an MBA from Columbia Business School.
Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations
Richard Labelle joined Medexus (Pediapharm legacy) in February of 2014. Previously he was the general manager and vice president of the consumer portfolio at Sanofi. He has held several management positions including heading commercial operations for the cardiovascular and osteoporosis divisions. He also led the business development team at Aventis. Mr. Labelle holds a Bachelor of Commerce from University of Quebec and a Master of Business Administration from McGill – HEC executive program.
Vice President Specialty Markets, Canadian Operations
Kerry Bakewell joined Medexus in January of 2002, as Director of Sales and Marketing. She has over 30 years of experience in the pharmaceutical industry, including several management positions at Merck Frosst and Sanofi. She has played an integral role in the growth and success of the Specialty Markets Division in Canada. Miss Bakewell holds a Bachelor of Science degree from The University of Alberta.